Sat, February 21, 2026
Fri, February 20, 2026

Sonova Lowers Full-Year Revenue Outlook Amid North American Challenges

Zurich, Switzerland - February 21st, 2026 - Sonova, a global leader in hearing solutions, announced today that it anticipates full-year revenue will land at the lower end of its previously communicated target range. The announcement, made by CEO Christophe Badoux in an interview, signals a shift in expectations due to emerging challenges within the crucial North American market. This development comes amidst a period of significant innovation and ongoing strategic investment by the Swiss hearing aid manufacturer.

Sonova, known for its brands like Phonak, Unitron, and Hansaton, has historically enjoyed consistent growth, fuelled by an aging global population and increasing awareness of hearing loss. However, the North American market - a key revenue driver for the company - is now experiencing a confluence of factors that are impacting performance. Badoux cited slower growth rates and a marked increase in competition as primary concerns. While the specific competitors weren't named, industry analysts point to a rising number of direct-to-consumer hearing aid providers and increased activity from established players like WS Audiology, creating a more crowded and competitive landscape.

"We're seeing a bit more of a challenging environment in North America," Badoux stated, acknowledging the changing dynamics. "We think that we are going to be at the lower end of our target range for the full year." This cautious outlook represents a departure from earlier, more optimistic projections and underscores the severity of the headwinds encountered.

The factors contributing to the slower growth in North America are complex. Increased economic uncertainty, particularly regarding healthcare costs and insurance coverage, is impacting consumer spending on discretionary items like hearing aids. While hearing aids are increasingly recognized as essential medical devices, out-of-pocket expenses can still be substantial for many individuals, leading to delayed purchases or a preference for more affordable options.

Furthermore, the recent implementation of the Over-the-Counter (OTC) hearing aid rule in the United States has introduced a new tier of competition. While initially viewed as a potentially disruptive force, the OTC market's impact has been nuanced. While it has broadened access to hearing solutions for those with mild to moderate hearing loss, it has also fragmented the market and introduced price pressure. Sonova, while embracing innovation in this space, is carefully navigating the challenges presented by this new regulatory landscape.

Despite the short-term challenges, Sonova remains committed to its long-term growth strategy. Badoux emphasized the company's continued investment in research and development, particularly in areas like advanced signal processing, artificial intelligence, and connectivity. These investments are aimed at delivering next-generation hearing solutions that address the evolving needs of individuals with hearing loss. The company is heavily focused on personalized hearing experiences, leveraging data and machine learning to tailor solutions to individual hearing profiles and lifestyles.

Beyond internal innovation, Sonova is actively pursuing strategic acquisitions to bolster its portfolio and expand its reach. Badoux indicated that the company is exploring opportunities in adjacent markets, such as diagnostic services, audiological software, and remote hearing care. The goal is to create a more comprehensive and integrated hearing healthcare ecosystem. Recent speculation in the industry suggests Sonova is evaluating several potential targets, with a particular interest in companies specializing in telehealth solutions for hearing care. [Link to potential acquisition targets - placeholder for actual link]

Analysts suggest that a successful acquisition could provide Sonova with a significant competitive advantage, allowing it to offer a broader range of services and enhance customer loyalty. However, the company will need to carefully evaluate potential targets to ensure a strong strategic fit and a positive return on investment.

The revised revenue outlook will undoubtedly be scrutinized by investors in the coming months. However, Sonova's track record of innovation and its commitment to strategic growth suggest that the company is well-positioned to navigate the current challenges and maintain its leadership position in the global hearing solutions market. The company's next earnings call, scheduled for March 15th, is expected to provide further clarity on its strategic initiatives and its outlook for the remainder of the fiscal year. [Link to Sonova Investor Relations page - placeholder for actual link]


Read the Full reuters.com Article at:
[ https://www.reuters.com/business/healthcare-pharmaceuticals/sonova-expects-fy-revenue-lower-end-target-range-ceo-says-interview-2026-02-20/ ]